Clinical Trial Update: Histamine Receptor 2 Antagonists as Enhancers of Anti-Tumour Immunity [Phase 4]

View source ↗

Summary

Phase 4 clinical trial examining histamine H2 receptor antagonists as enhancers of anti-tumor immunity in cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Histamine H2 receptor antagonists

Snippet

Sponsor: Nova Scotia Health Authority | Conditions: Cancer | Phase 4 | Status: COMPLETED